Medical News

June 4, 2004 — Research and Markets announces the addition of this new report entitled “Analytical Tool: Frontlines in Cancer Therapeutics I” to its offerings.

In this very extensive Analytical Tool, a number of fields and topics have been selected in cancer therapy R&D, which have all seen tremendous advancements lately. Monoclonal antibodies, anti-angiogenesis / vascular targeting, protein kinase inhibitors, integrin antagonists, VEGF-Trap and Endostatin are covered in a number of reports and databases, included in this Analytical Tool. This range of therapeutic strategies and targets include many strong interrelationships in terms of technology, R&D and competition. An example of this is Avastin, a monoclonal antibody targeting the VEGF signaling pathway, partly resulting in an antiangiogenetic effect.

With the products included in this Analytical Tool, some of the most active, competitive and interesting fields can be seen in oncology today. While providing a complete overview of these topics, this package will also allow the opportunity to carry out independent in-depth analysis on these fields, thanks to the immense and complete data sets included. This Analytical Tool also forecasts the developmental progress in terms of indications, type of drugs, drug effects, targets, and mechanism of actions. Hundreds of companies and their activities are described and evaluated. More than 1000 cancer projects are included.

This analytical tool will help to:
- Track down cutting edge companies and emerging products, therapies or technologies
- Identify potential partners and competitors
- Produce presentations related to the development of new therapeutics
- Identify R&D trends and their effects for the future product pipeline
- Lay down a comprehensive framework for further analysis of the field
- Rapidly perform advanced search queries to find the information you need
- Generate specific and relevant tables and graphs based on specific search queries, in order to aid you in the decision-making process

Products included in Frontlines in Cancer Therapeutics I:
- New Lines of Attack in Cancer Anti-Angiogenesis
- Antibodies as Cancer Therapeutics - R&D Situation & Business Perspectives
- Cancer Pipeline Valuation: VEGF Trap (Regeneron) - A Deal Worth more than $500M?
- Commercializing on Protein Kinase Inhibitors
- Cancer Pipeline Valuation: Endostatin - Will Continued Effort Generate Value?
- Improved Monoclonals on the Rise
- Integrin Antagonists - Is the Industry in Despair?
- Late Stage Protein Kinase Inhibitors
- Protein Kinase Inhibitors Database
- Antiangiogenesis / Vascular Targeting Database
- Monoclonal Antibodies Database

This Analytical Tool includes advanced software to summarize and analyze the text in the reports included. This feature can rapidly summarize the complete material (or selected parts thereof). This feature can also produce “keyword extractions”, enabling a quick and easy scan through the most important parts of this immense material.

For a complete index of this report click on http://www.researchandmarkets.com/reports/74826

About Research and Markets Ltd.
Research and Markets Ltd. are Europe’s largest resource for market research. R&M distribute thousands of major research publications from the world’s leading publishers, consultants and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends.

For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com or mailto:press@researchandmarkets.com

June 4, 2004 — Research and Markets announces the addition of this new report entitled “Analytical Tool: Frontlines in Cancer Therapeutics I” to its offerings.

In this very extensive Analytical Tool, a number of fields and topics have been selected in cancer therapy R&D, which have all seen tremendous advancements lately. Monoclonal antibodies, anti-angiogenesis / vascular targeting, protein kinase inhibitors, integrin antagonists, VEGF-Trap and Endostatin are covered in a number of reports and databases, included in this Analytical Tool. This range of therapeutic strategies and targets include many strong interrelationships in terms of technology, R&D and competition. An example of this is Avastin, a monoclonal antibody targeting the VEGF signaling pathway, partly resulting in an antiangiogenetic effect.

With the products included in this Analytical Tool, some of the most active, competitive and interesting fields can be seen in oncology today. While providing a complete overview of these topics, this package will also allow the opportunity to carry out independent in-depth analysis on these fields, thanks to the immense and complete data sets included. This Analytical Tool also forecasts the developmental progress in terms of indications, type of drugs, drug effects, targets, and mechanism of actions. Hundreds of companies and their activities are described and evaluated. More than 1000 cancer projects are included.

This analytical tool will help to:
- Track down cutting edge companies and emerging products, therapies or technologies
- Identify potential partners and competitors
- Produce presentations related to the development of new therapeutics
- Identify R&D trends and their effects for the future product pipeline
- Lay down a comprehensive framework for further analysis of the field
- Rapidly perform advanced search queries to find the information you need
- Generate specific and relevant tables and graphs based on specific search queries, in order to aid you in the decision-making process

Products included in Frontlines in Cancer Therapeutics I:
- New Lines of Attack in Cancer Anti-Angiogenesis
- Antibodies as Cancer Therapeutics - R&D Situation & Business Perspectives
- Cancer Pipeline Valuation: VEGF Trap (Regeneron) - A Deal Worth more than $500M?
- Commercializing on Protein Kinase Inhibitors
- Cancer Pipeline Valuation: Endostatin - Will Continued Effort Generate Value?
- Improved Monoclonals on the Rise
- Integrin Antagonists - Is the Industry in Despair?
- Late Stage Protein Kinase Inhibitors
- Protein Kinase Inhibitors Database
- Antiangiogenesis / Vascular Targeting Database
- Monoclonal Antibodies Database

This Analytical Tool includes advanced software to summarize and analyze the text in the reports included. This feature can rapidly summarize the complete material (or selected parts thereof). This feature can also produce “keyword extractions”, enabling a quick and easy scan through the most important parts of this immense material.

For a complete index of this report click on http://www.researchandmarkets.com/reports/74826

About Research and Markets Ltd.
Research and Markets Ltd. are Europe’s largest resource for market research. R&M distribute thousands of major research publications from the world’s leading publishers, consultants and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends.

For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com or mailto:press@researchandmarkets.com